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A majority of patients with ischemic stroke present with mild deficits for which aggressive 
management is not often pursued. Comprehensive work-up and appropriate interven-
tion for minor strokes and transient ischemic attacks (TIAs) point toward better patient 
outcomes, lower costs, and fewer cases of disability. Imaging is a key modality to guide 
treatment and predict stroke recurrence. Patients with large vessel occlusions have been 
found to suffer worse outcomes and could benefit from intervention. Whether intrave-
nous thrombolytic therapy decreases disability in minor stroke patients and whether 
acute endovascular intervention improves functional outcomes in patients with minor 
stroke and known large vessel occlusion remain controversial. Studies are ongoing to 
determine ideal antiplatelet therapy for stroke and TIA, while ongoing statin therapy, 
surgical management for patients with carotid stenosis, and anticoagulation for patients 
with atrial fibrillation have all been proven to decrease the rate of stroke recurrence and 
improve outcomes. This review summarizes the current evidence and discusses the 
standard of care for patients with minor stroke and TIA.
Keywords: minor stroke, transient ischemic attack, minor stroke outcome, treatment, recurrent stroke risk, stroke 
prevention
BACKGROUND
In population-based studies, approximately two-thirds of ischemic stroke patients have mild 
deficits (1, 2). Minor stroke is generally defined as an National Institute of Health Stroke Scale 
(NIHSS) of 5 or less, which takes into account certain deficits but not the fact that some can have 
a more profound impact on quality of life than others. Hence, the scale does not linearly correlate 
deficit and disability. While studies suggest using an NIHSS of 3 or less to define minor stroke (3, 4), 
real-world definitions of non-disabling deficits are largely dependent on clinical judgment, which 
has been shown to vary widely among physicians (5). Transient ischemic attack (TIA) has a more 
widely accepted definition that includes focal neurological symptoms lasting for <24 h without the 
presence of infarction on diffusion-weighted imaging (6).
In clinical practice, both minor stroke and TIA patients undergo similar diagnostic evaluations. 
Due to the relatively high early risk of stroke recurrence in both groups and disability in minor 
stroke patients, key decisions in the management of minor strokes and TIA can have significant 
impacts on clinical outcomes, quality of life, and cost of care. In this review, we summarize the 
TABLe 1 | Clinical stroke risk recurrence scores (23).
Score ABCD2 ABCD3 ABCD3-i
Components:
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(2)
(2)
Age > 60 years
BP ≥ 140/90 mmHg
Clinical features:
 – Speech impaired w/o weakness
 – Unilateral weakness
 – Duration 10–59 min
 – ≥60 min
 – Diabetes Mellitus
Age > 60 years
BP ≥ 140/90 mmHg
Clinical features:
 – Speech impaired w/o weakness
 – Unilateral weakness
 – Duration 10–59 min
 – ≥60 min
 – Diabetes Mellitus
 – Dual TIA within 7 days
Age > 60 years
BP ≥ 140/90 mmHg
Clinical features:
 – Speech impaired w/o weakness
 – Unilateral weakness
 – Duration 10–59 min
 – ≥60 min
 – Diabetes Mellitus
 – Dual TIA within 7 days
 – Intra and extracranial imaging with 
≥50% stenosis of ipsilateral large artery
Approximate stroke incidence (%)  
in high-risk patients after
(Score 6–7) (Score 6–9) (Score 8–13)
7 days 10 9 14
90 days 12 12 15
3 years 28 28 30
2
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current research on minor stroke and TIA, and highlight key 
points in acute treatment and secondary stroke prevention 
strategies.
ACUTe TReATMeNT
Thrombolytic Therapy
Thrombolytic therapy with intravenous recombinant tissue 
plasminogen activator (IV rtPA) is an important treatment for 
patients with acute ischemic stroke (7). Patients with minor 
deficits are often excluded from such treatment even though 
they demonstrate a high rate of suboptimal functional outcome. 
While retrospective studies show no benefit in 3-month outcome 
between thrombolysed and non-thrombolysed patients with 
mild deficits (8, 9), these studies are subject to selection bias in 
favor of treating patients with disabling versus non-disabling 
deficits. Recent evidence from a stroke registry supports the 
use of IV rtPA compared with routine medical management 
in patients with mild deficits (10). In addition, a post  hoc 
analysis of the International Stroke Trial-3 (IST-3) found that 
patients with mild deficits who were treated IV rtPA compared 
to placebo had a favorable shift in the Oxford Handicap Scale 
distribution (adjusted odds ratio, 2.38; 95% confidence interval, 
1.17–4.85). The most feared complication of IV rtPA is symp-
tomatic intracerebral hemorrhage (sICH), which is seen in up 
to 2% of patients with minor stroke (11–13). Due to the fear of 
hemorrhagic complications, physicians tend to offer IV rtPA to 
patients who they consider to have a disabling deficit, a highly 
subjective clinical judgment. The subjectivity of this approach 
highlights the need for prospective cohorts to better understand 
the natural history and predictors of long-term functional and 
cognitive outcomes in patients with minor stroke, taking into 
account the type of deficit, the patient, and potential for stroke 
recovery. Two randomized clinical trials comparing IV rtPA 
versus placebo in patients with minor non-disabling deficits are 
underway (14, 15).
Acute endovascular Therapy
Several clinical trials recently showed that the addition of 
mechanical thrombectomy to best medical treatment in patients 
with acute ischemic stroke and evidence of a large artery occlu-
sion resulted in significant improvement in long-term functional 
outcomes (16). Most of these studies excluded patients with 
minor stroke leading to variability in the use of mechanical 
thrombectomy for patients with acute large vessel occlusion and 
transient or minor deficits. Large vessel occlusion is an important 
and consistent predictor of neurological deterioration and dis-
ability in patients with minor stroke (17, 18). Excluding these 
patients from endovascular treatment may lead to a sevenfold 
increased risk of long-term disabling deficits and up to 50% of 
patients being functionally disabled at 3 months (17, 18). Recent 
AHA/ASA guidelines suggest that it is reasonable to consider 
endovascular treatment for patients with an NIHSS score <6 and 
evidence of large vessel occlusion. However, clinical trials are 
needed to prove the efficacy of endovascular treatment in this 
patient population (19).
RiSK OF ReCURReNT STROKe
The risk of recurrent stroke in patients with minor stroke and 
TIA is 10–13% at 90  days, with approximately half of events 
occurring in the first 2 days (20, 21). Multiple scores have been 
used to predict the early risk of stroke after a TIA or minor 
stroke, including the ABCD2 score (22, 23) and the ABCD3-I 
(24) score that include neurovascular and MR imaging (Table 1). 
Studies have shown imaging-supplemented scores to be superior 
to clinical scores alone in predicting stroke recurrence in patients 
with minor stroke or TIA (25, 26). In a meta-analysis of 29 studies 
and over 130,000 patients, the ABCD2 score lacked reliability in 
predicting early recurrent stroke risk and in identifying patients 
with symptomatic large artery atherosclerosis (27), an important 
prognosticator of early stroke recurrence (25, 28, 29). In fact, 
a recent multi-center study showed that in patients with minor 
TABLe 2 | Detection rates of paroxysmal atrial fibrillation using various 
cardiac monitoring strategies (42).
Type of monitoring Setting Duration Rate of detection of 
atrial fibrillation (%)
Admission ECG Inpatient N/A 2.7
Inpatient continuous 
telemetry
Inpatient 24–48 h 5.5
Holter monitor Outpatient 24–48 h 3.2–6.4
Mobile continuous 
outpatient telemetry
Outpatient 21–28 days 16–25
Implantable loop 
recorders
Outpatient 6 months 9
36 months 30
3
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stroke or TIA, the risk of early stroke recurrence or neurological 
deterioration was only up to 2% in the absence an infarction 
on neuroimaging or large artery disease stroke subtype and 
approximately 30% in those with large artery disease stroke 
subtype who have an infarction on neuroimaging. In this study, 
the ABCD2 score was not a predictor of stroke recurrence (30). 
Another study showed that the addition of perfusion imaging 
to parenchymal and vascular imaging in patients with minor 
stroke TIA improved prediction of recurrent cerebrovascular 
events (31).
SeCONDARY STROKe PReveNTiON
Acute Antiplatelet Agents
Due to the relatively high early risk of recurrent stroke in 
patients with minor stroke or TIA as compared to those with 
larger stroke severity, secondary stroke prevention is one of 
the most important steps in improving outcome in this patient 
population. Secondary prevention strategies include the use of 
antiplatelet agents, statins, and aggressive risk factor modifica-
tion (32). Aggressive therapies targeting platelet inhibition in 
the absence of indications for anticoagulation is of paramount 
importance. Aspirin when administered within 48  h of an 
ischemic stroke has been shown to be effective in reducing 
the 2-week risk of stroke (2.8–3.3 versus 3.9%) (33, 34). The 
Clopidogrel with Aspirin in Acute Minor Stroke or Transient 
Ischemic Attack (CHANCE) trial, which included patients 
with TIA and minor stroke (NIHSS score ≤3) and excluded 
patients with isolated sensory symptoms, isolated dizziness, 
or isolated visual changes found an advantage of short-term 
dual antiplatelet therapy (aspirin plus clopidogrel) over aspirin 
monotherapy in the occurrence of secondary stroke (20). An 
important caveat about the CHANCE trial is that less than 
half of patients received a lipid-lowering drug and only about 
one-third received antihypertensive treatment, which is a very 
different management style in North America. In addition, the 
event rates, which were close to 10% in both arms far exceed the 
current rate of secondary stroke in North America – estimated 
at <5%. The ongoing Platelet-Oriented Inhibition in New TIA 
and Minor Ischemic Stroke Trial (POINT) is assessing a similar 
population in North America with more robust use of statins 
and antihypertensive agents to see whether the results observed 
in CHANCE will be replicated. Short-term dual antiplatelet 
therapy has been used for secondary stroke prevention in 
patients with symptomatic intracranial atherosclerotic disease 
(35), symptomatic carotid disease to reduce the number of 
micro-embolic signals (36), and in those with stuttering 
lacunar stroke (37, 38) with a potential reduction of stroke 
risk. While the bleeding risk of long-term dual antiplatelet 
therapy is higher than that of aspirin alone (39), there is 
evidence to support the safety of such treatment when used 
on a short-term basis when the risk of recurrent stroke is 
highest without an increase in ICH (20). Furthermore, the 
short-term use of ticagrelor, another antiplatelet agent used 
for acute coronary syndrome, was compared with aspirin in 
patients with TIA and minor stroke in the SOCRATES trial 
(Acute Stroke Or Transient IsChaemic Attack TReated With 
Aspirin or Ticagrelor and Patient OutcomES). Results of this 
trial showed no significant difference in recurrent events 
between the two groups.
Statin Therapy
In addition to their effect on lowering cholesterol, statins have 
neuroprotective and anti-inflammatory properties that enhance 
endothelial function and promote blood flow (40). A small 
randomized study (41) and a larger retrospective study (42) 
showed that patients who were continued on a statin acutely after 
a stroke had a better outcome than those in whom the statin was 
withdrawn. Therefore, in patients with minor stroke or TIA, early 
continuation of statin therapy may improve both short-term and 
long-term stroke prevention strategies.
Carotid Revascularization
Evaluation for carotid stenosis is a key step in the diagnostic evalu-
ation of patients with TIA and minor stroke. In patients with this 
disease, surgical management in addition to best medical therapy 
is superior to best medical therapy alone, particularly in those 
with >70% symptomatic stenosis (43). While medical treatment 
for stroke prevention has improved, carotid endarterectomy or 
carotid artery stenting still remain an integral part of the treat-
ment for patients with severe symptomatic carotid stenosis. Since 
the risk of recurrent stroke in such patients is highest in the first 
2 weeks after their initial event (44), the AHA/ASA recommends 
urgent surgery within 2 weeks of symptoms (32).
Atrial Fibrillation Detection
Identifying atrial fibrillation is important in secondary stroke 
prevention as anticoagulation is superior to antiplatelet agents 
in reducing the stroke risk of patients with atrial fibrillation. 
Electrocardiogram and inpatient cardiac telemetry should be 
part of diagnostic evaluation of patients admitted with ischemic 
stroke (32). Longer cardiac monitoring via mobile continuous 
outpatient telemetry (MCOT) or implantable loop records may 
be indicated in patients with cryptogenic stroke to increase the 
yield of detecting paroxysmal atrial fibrillation (45). Since the 
detection rates are higher with MCOT or loop recorders when 
compared to inpatient telemetry, patients with mild deficits do 
not need to be admitted solely for inpatient telemetry. Detection 
rates of paroxysmal atrial fibrillation using various cardiac moni-
toring are shown in Table 2.
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TRiAGiNG AND DiSPOSiTiON
Any acute, symptomatic stroke-like symptom (transient or 
not) should be considered a medical emergency. Interventions 
should be limited at this point to streamline the acquisition of 
a non-contrast CT scan of the brain to exclude the presence 
of any intracranial hemorrhage. Patients in whom an acute 
large vessel occlusion of the anterior or posterior circulation 
is suspected should be considered for upfront CT angiographic 
imaging as well. An exception is made for patients who expe-
rienced entirely fleeting symptoms and have returned to their 
neurologic baseline. In these patients, a CT scan can be forgone 
in lieu of a diffusion-weighted MRI provided hospital resources 
allow for urgent imaging acquisition (within 24  h) and the 
patient has no contraindications to MRI. As recommended by 
the AHA/ASA, all patients with TIA should undergo brain and 
cervico-cephalic vascular imaging routinely as part of their 
initial evaluation (7).
A detailed neurological exam that includes, but is not limited, 
to an NIHSS should be completed in all cases. The provider 
should remain vigilant of subtle neurological dysfunction, as 
patients may report symptom resolution, but still exhibit focal 
abnormalities. This occurred in 26% of patients referred to a 
same-day TIA clinic when examined by a neurologist in one 
study (46).
Determining which TIA patients require inpatient hospitaliza-
tion is largely a factor of institutional resources and the ease of 
access for patients to receive follow-up care. As such, significant 
practice variability exists between providers and institutions and 
this has been a source of frequent debate. On the whole, some-
where between 53 and 91% of all TIA patients presenting to U.S. 
emergency departments (EDs) are admitted (47–53). The focus 
should be on determining the underlying etiology of the ischemic 
event and optimizing individual secondary prevention strategies. 
Large artery atherosclerosis can be effectively ruled out with 
brain imaging and vascular imaging of the head and neck (CTA, 
MRA, or carotid Duplex and transcranial Doppler ultrasound). 
Cardioembolic etiologies should be explored with electrocardio-
gram and in-house telemetry, followed by echocardiography and 
prolonged holter monitoring in selected patients. The suspected 
etiology of the ischemic event should be classified into the best of 
the provider’s ability at the time of the initial encounter. ED wait 
times and limited emergency neurology expertise availability 
are common drivers for hospitalization. Another determinant 
of hospitalization is the presence of disabling deficits in gait 
or swallowing requiring inpatient physical and speech therapy 
evaluations.
Rapid access TIA clinics and ED observation units provide 
efficient and cost-effective alternatives to hospitalization for 
many patients. Observation units, typically located within or near 
the hospital EDs, provide expedited and protocol-driven care and 
have a proven track record of safety with TIA (54–57). Outpatient 
clinics, such as the French SOS-TIA and British EXPRESS 
models, have successfully implemented 24/7 urgent outpatient 
follow-up for TIA, while reducing 90-day stroke recurrence 
by 80% (58–60). As stroke systems of care are increasingly 
regionalized and hospitals become increasingly incentivized 
to optimize cost-effective care and decrease inpatient length of 
stay, these models will likely be increasingly utilized.
Risk stratification tools, such as the ABCD2 score, have been 
implemented in some systems to triage the urgency of follow-up 
or determine in whom hospitalization is advised. Current NICE 
criteria and AHA/ASA guidelines both support this practice, 
which was found to be safe in a recent Australian study (6, 7, 
53, 61). However, as discussed in the preceding section, clinical 
risk stratification tools are rather imperfect and the more robust-
imaging enhanced tools include definitive (and often inpatient) 
advanced imaging modalities. While clinical risk prediction may 
be used to augment one’s gestalt of a patient’s short-term recur-
rent stroke risk, it should not be used as the sole determinant of 
disposition. Adopting a frontloaded, etiology-focused work-up 
that optimizes individual secondary prevention strategies is likely 
to be the best approach, regardless of location (hospital, clinic, or 
observation unit) (62).
OUTCOMe
Approximately 30% of patients with minor strokes have poor 
functional outcomes [defined as modified Rankin scale (mRS) 
score of 2–6] at 90 days (3, 63). Furthermore, nearly one-third 
of patients admitted to the hospital for a mild stroke are not 
discharged home (64, 65) and cannot walk independently at 
discharge (64). A consistent predictor of outcome in patients 
with minor deficits is evidence of large vessel occlusion on imag-
ing (17, 18). However, absence of large vessel occlusion is also 
associated with substantial long-term disability (17, 18). Studies 
exploring the type of deficits as predictors of outcome in patients 
with minor stroke yield mixed results. One study showed that 
the types of deficits do not predict outcome in minor stroke 
(66). Another study showed that certain items not included in 
the NIHSS score, such as distal hand weakness and gait disor-
der, increase the likelihood of a poor functional outcome after 
a minor stroke (67). Other items of the NIHSS that have been 
associated with poor outcome in studies include language deficits 
(67), neglect (68), and leg weakness (68). The NIHSS score and 
outcome measures assessed in prior studies, such as mRS can 
underestimate cognitive deficits (69), particularly visuospatial 
or executive dysfunction (70), and post-stroke fatigue (71) that 
can occur after a minor stroke. These deficits may cause long-
term disability after a mild stroke. Therefore, capturing more 
sensitive impairment measures that include gait speed, simplified 
neuropsychological assessments, and examination of distal hand 
strength and dexterity may aid in making treatment decisions in 
patients with otherwise mild deficits. Patient-related factors, such 
as baseline functional status, hobbies, and occupation, may also 
help treating physicians decide the degree to which the nature of 
deficits may affect patients’ functional outcome.
CONCLUSiON
A comprehensive approach to the treatment and triaging of 
patients with minor stroke or TIA may lead to decreased long-
term functional deficits in this patient population and still be 
cost-effective. Randomized trials exploring several treatments 
5Yakhkind et al. Minor Stroke and TIA
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and outcome predictors in patients with TIA and minor stroke 
are underway and aim to advance management and reduce the 
degree of functional disability.
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